We are live on
!
Find out more
First Manhattan Portfolio holdings
AUM
$36.1B
1-Year Est. Return
11.5%
This Fund
S&P 500
This Quarter
Est. Return
+9.64%
1 Year Est. Return
+11.5%
3 Year Est. Return
+74.65%
5 Year Est. Return
+103.66%
10 Year Est. Return
+354.63%
AUM
$27.3B
AUM Growth
+$1.22B
(+4.7%)
Cap. Flow
-$932M
Cap. Flow
% of AUM
-3.41%
Top 10 Holdings %
Top 10 Hldgs %
60.57%
Holding
1,588
New
70
Increased
176
Reduced
495
Closed
161
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Thermo Fisher Scientific
TMO
|
+$128M |
| 2 |
ATVI
Activision Blizzard
ATVI
|
+$67.4M |
| 3 |
XIFR
XPLR Infrastructure LP
XIFR
|
+$63.8M |
| 4 |
UnitedHealth
UNH
|
+$57.4M |
| 5 |
Danaher
DHR
|
+$24.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Berkshire Hathaway Class A
BRK.A
|
+$760M |
| 2 |
Amazon
AMZN
|
+$68.5M |
| 3 |
AbbVie
ABBV
|
+$54.2M |
| 4 |
PPLI
People Inc
PPLI
|
+$36.8M |
| 5 |
PNC Financial Services
PNC
|
+$29.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 44.09% |
| 2 | Technology | 18.28% |
| 3 | Healthcare | 10.34% |
| 4 | Consumer Discretionary | 7.89% |
| 5 | Communication Services | 5.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
476
Vipshop
VIPS
$6.84B
| $487K | ﹤0.01% |
+29,531
| New | +$462K |
|
477
Vanguard Total International Stock ETF
VXUS
$153B
| $485K | ﹤0.01% |
8,642
-73,481
| -89% | -$4.11M |
|
478
iShares Morningstar Mid-Cap Value ETF
IMCV
$1.13B
| $483K | ﹤0.01% |
7,581
+1
| +0% | +$61 |
|
479
TransDigm Group
TDG
$69.2B
| $482K | ﹤0.01% |
539
+9
| +2% | +$7.12K |
|
480
Qualcomm
QCOM
$176B
| $482K | ﹤0.01% |
4,046
-925
| -19% | -$106K |
|
481
Blue Owl Capital
OWL
$6.39B
| $481K | ﹤0.01% |
41,300
-9,071
| -18% | -$97.6K |
|
482
Chipotle Mexican Grill
CMG
$40.8B
| $475K | ﹤0.01% |
11,100
+50
| +0.5% | +$1.98K |
|
483
BridgeBio Pharma
BBIO
$16.5B
| $473K | ﹤0.01% |
27,490
| – | – |
|
484
Ramaco Resources Class A
METC
$676M
| $471K | ﹤0.01% |
+57,726
| New | +$481K |
|
485
Dorchester Minerals
DMLP
$1.34B
| $470K | ﹤0.01% |
+15,700
| New | +$461K |
|
486
AstraZeneca
AZN
$263B
| $469K | ﹤0.01% |
3,275
+1,540
| +89% | +$227K |
|
|
BECN
487
DELISTED
Beacon Roofing Supply, Inc.
BECN
| $467K | ﹤0.01% |
5,633
| – | – |
|
488
CoStar Group
CSGP
$11.3B
| $467K | ﹤0.01% |
5,244
+244
| +5% | +$18.8K |
|
489
Citizens Community Bancorp
CZWI
$227M
| $466K | ﹤0.01% |
52,624
| – | – |
|
490
Edwards Lifesciences
EW
$47.6B
| $463K | ﹤0.01% |
4,911
| – | – |
|
491
Franklin Resources
BEN
$16.9B
| $459K | ﹤0.01% |
17,200
-1,350
| -7% | -$34.9K |
|
492
Veeva Systems
VEEV
$30.3B
| $455K | ﹤0.01% |
2,300
| – | – |
|
493
Ares Capital
ARCC
$13.5B
| $454K | ﹤0.01% |
24,163
| – | – |
|
494
iShares Russell 1000 Growth ETF
IWF
$122B
| $452K | ﹤0.01% |
6,568
| – | – |
|
495
Prestige Consumer Healthcare
PBH
$2.35B
| $452K | ﹤0.01% |
+7,600
| New | +$455K |
|
496
SB Financial Group
SBFG
$160M
| $450K | ﹤0.01% |
35,627
| – | – |
|
497
Equifax
EFX
$20.3B
| $449K | ﹤0.01% |
1,910
-18
| -0.9% | -$3.79K |
|
498
Medtronic
MDT
$107B
| $449K | ﹤0.01% |
5,093
-1,373
| -21% | -$118K |
|
499
Vanguard Mid-Cap Growth ETF
VOT
$19B
| $448K | ﹤0.01% |
2,177
-1,545
| -42% | -$299K |
|
500
Acadia Realty Trust
AKR
$2.99B
| $443K | ﹤0.01% |
30,771
| – | – |
|
Similar funds
SAM
First Manhattan's Q2 2023 Portfolio in Review
As of Q2 2023, First Manhattan held 1,588 positions worth $27.3B, up 4.7% from $26.1B the previous quarter. Its ten largest holdings account for 61% of the portfolio.
First Manhattan withdrew a net $932M in Q2 2023, closing 161 positions and reducing 495 holdings. Its most notable exit was Enanta Pharmaceuticals, an estimated $10.7M position sold in full.
By sector, the portfolio is most concentrated in Financials at 44% of assets, down from 45% a quarter earlier, followed by Technology and Healthcare.
Against the trend, First Manhattan opened a new position in Mersana Therapeutics worth $1.87M.
- First Manhattan's largest Q2 2023 buy was Mersana Therapeutics: 22,784 shares worth $1.87M.
- First Manhattan added most to Thermo Fisher Scientific in Q2 2023, an estimated $128M increase.
- First Manhattan's biggest Q2 2023 reduction was Berkshire Hathaway Class A, cutting an estimated $760M.
- First Manhattan fully exited Enanta Pharmaceuticals in Q2 2023, selling an estimated $10.7M.
- First Manhattan's ten largest holdings make up 61% of its $27.3B portfolio in Q2 2023.
- First Manhattan opened 70 new positions and closed 161 in Q2 2023.
- First Manhattan's portfolio value rose 4.7% quarter-over-quarter to $27.3B.
Based on First Manhattan's 13F filing for Q2 2023, filed 14 Aug 2023.